Accessibility Menu
Imugene logo

Imugene(OTC) IUGNF

Market Cap$40.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-52%
5 Year-99%
1 Year-53%
1 Month+1%
$0.07
-9.15%
-0.01Today
Imugene last closing stock price
MetricPriceDate
Last closeUSD 0.082026-08-19
Imugene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.59%USD 0.082026-08-12
1 month+0.65%USD 0.082026-07-20
3 month+17.11%USD 0.072026-05-21
Year to date-68.47%USD 0.262025-12-31
1 year-52.91%USD 0.172025-08-19
3 year-95.41%USD 1.792023-08-18
5 year-98.82%USD 6.972021-08-20
Since inception-51.78%USD 0.172019-07-05

Imugene Financials at a Glance

Market Cap

$40.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.30M

Net Income (TTM)

-A$187.79M

EPS (TTM)

-$0.14

P/E Ratio

-0.57

Dividend

$0.00

Beta (Volatility)

-2.53 (Low)

Price

$0.07

Volume

3,493

Open

$0.10

Previous Close

$0.08

Daily Range

$0.07 - $0.10

52-Week Range

$0.04 - $0.31

Estimated Earnings Date

Sep 2, 2026

IUGNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imugene

Imugene Limited is an Australian biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company aims to activate the immune systems of cancer patients to effectively combat malignant growths, with a strong emphasis on clinical-stage immuno-oncology.

Products and Services
  • HER-Vaxx: A vaccine targeting HER2-positive cancers, currently in Phase 1b/2 trials for gastric cancer
  • PD1-Vaxx: Designed to induce polyclonal antibodies that block PD-1 signaling in cancer treatment
  • CF33: An oncolytic virus developed from various vaccinia virus strains for solid tumor therapy
Growth Outlook
  • HER-Vaxx is progressing through clinical trials, potentially expanding treatment options for gastric cancer
  • Strategic partnerships with Celularity and Eureka Therapeutics enhance research capabilities and market reach
  • Continued investment in R&D positions Imugene for future breakthroughs in immunotherapy
Financial Highlights
  • Recent quarterly revenue of AUD 8.068 million indicates growth potential despite ongoing losses
  • Cash and cash equivalents stood at AUD 14.131 million, providing operational runway for upcoming projects
  • Operating expenses for the latest quarter were AUD 40.409 million, reflecting significant investment in R&D
Imugene Limited is dedicated to advancing cancer treatment through innovative immunotherapies. The company's lead product, HER-Vaxx, is currently undergoing clinical evaluation, which could significantly impact treatment options for patients with HER2-positive cancers. The strategic partnerships with Celularity and Eureka Therapeutics further bolster the company's research capabilities, potentially leading to groundbreaking advancements in the field. Financially, while the company is currently operating at a loss, the recent revenue growth and substantial cash reserves indicate a commitment to long-term development and innovation in cancer therapies.
AI Generated • Aug 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

23

CEO

Leslie Chong

Website

imugene.com

Headquarters

Sydney, NSW 2000, AU

IUGNF Financials

Key Financial Metrics (TTM)

Gross Margin

-65.91%

Operating Margin

-1960.77%

Net Income Margin

-1864.12%

Return on Equity

-134.65%

Return on Capital

-127.40%

Return on Assets

-86.46%

Earnings Yield

-1.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$40.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

489.72M

Volume

3.49K

Avg. Volume

14.87K

Financials (TTM)

Gross Profit

-A$3.91M

Operating Income

-A$178.91M

EBITDA

-A$178.95M

Operating Cash Flow

-A$150.43M

Capital Expenditure

-A$5.51M

Free Cash Flow

-A$155.94M

Cash & ST Invst.

A$14.13M

Total Debt

A$5.02M

Imugene Performance Analysis

Imugene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Imugene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-138.4%
Q22024-12-31140.6%
Q42025-06-30149.5%
Q22025-12-31-100.0%
Imugene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.17N/A
20232023-06-30AUD -0.14-16.7%
20242024-06-30AUD -0.47240.8%
20252025-06-30AUD -0.20-56.6%
Imugene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-11.8%
Q22024-12-3142.1%
Q42025-06-3057.2%
Q22025-12-31-38.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$5.20M

-164.5%

Gross Margin

0.00%

N/A

Market Cap

$40.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.03M

N/A

Employees

5

N/A

Net Income

-A$37.81M

+45.0%

EBITDA

-A$40.06M

+42.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$14.13M

-89.9%

Total Debt

A$5.02M

-22.6%

Accounts Receivable

A$4.41M

-78.4%

Inventory

A$1.67M

N/A

Long Term Debt

A$48.23K

-98.8%

Short Term Debt

A$4.97M

+115.1%

Return on Assets

-86.46%

N/A

Return on Invested Capital

-1.25%

N/A

Free Cash Flow

-A$25.96M

+56.7%

Operating Cash Flow

-A$25.96M

+46.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BSEMBioStem Technologies, Inc.
$3.70+10.61%
PRNAFAlterity Therapeutics Limited
$0.35+0.00%
VSBCVitaSpring Biomedical Co. Ltd.
$0.01+0.00%
HSCHFH-Source Holdings Ltd.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.84+0.06%
IBITiShares Bitcoin Trust
$41.21+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.75-0.05%
SPCXSpace Exploration Technologies
$131.31-0.06%

Questions About IUGNF

What is the current price of Imugene?

Imugene is trading at $0.07 per share.

What is the 52-week range for Imugene?

Over the past 52 weeks, Imugene has traded between $0.04 and $0.31.

How much debt does Imugene have?

As of the most recent reporting period, Imugene reported total debt of A$6.98M.

How much cash does Imugene have on hand?

Imugene reported A$14.38M in cash and cash equivalents in its most recent financial results.

What is Imugene’s dividend yield?

Imugene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services